GlassScriptPhysician profile
Berhane Seyoum
NPI 1699702241
$10,543.33
in general payments reported to CMS, 2019-2025
43 companies · $1,488 in 2025
The $1,488 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,707 · 2020: $676 · 2021: $513 · 2022: $3,066 · 2023: $826 · 2024: $2,268 · 2025: $1,488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,748 · Travel and Lodging: $802 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,747.53 |
| Travel and Lodging | $801.92 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $4,759.48 | 2022-2025 | Minimed 780g, Minimed 770g, Inpen Smart Insulin Delivery System |
| Amgen INC. | $917.66 | 2019-2025 | Tepezza, Evenity, Prolia |
| Novo Nordisk INC | $843.70 | 2019-2025 | Ozempic, Wegovy |
| Lilly USA, LLC | $662.52 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Medtronic Minimed, INC. | $518.80 | 2019-2020 | |
| Corcept Therapeutics | $367.93 | 2020-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $211.08 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $186.61 | 2021-2024 | |
| Horizon Therapeutics Plc | $154.23 | 2019-2023 | Tepezza |
| Comsort, INC | $150.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $143.92 | 2021 | |
| Janssen Pharmaceuticals, INC | $124.76 | 2019 | |
| Pfizer INC. | $124.18 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $115.58 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.22 | 2019 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Berhane Seyoum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.